Charles River Laboratories shares gain almost 4% after raising 2026 GAAP EPS forecast and strong Q3 results

Traders Union
All News
Stocks
Charles river surges 3.85% today

Highlights

Charles River Laboratories reported third-quarter revenue of $982.73 million and net income of $333.07 million, raising its 2026 GAAP EPS guidance after reversing acquired tax reserves.
Organic revenue rose 4.7% on strong demand for safety assessment and manufacturing testing, and the company entered agreements to acquire Frontage Holdings bioanalysis and DMPK units.
Charles River Laboratories stock displays a bullish trend, with strong momentum and an 80% probability of moving higher in the $328.63 to $372.38 range over the next five days.

EPS outlook raised as organic growth and acquisitions drive optimism

Charles River Laboratories reported third-quarter revenue of $982.73 million and net income of $333.07 million, while raising its 2026 GAAP EPS guidance after reversing acquired tax reserves. The company also announced organic revenue growth of 4.7% for the quarter, supported by increased demand for safety assessment and manufacturing testing services. Charles River Laboratories disclosed definitive agreements to acquire Frontage Holdings’ bioanalysis and DMPK businesses as part of its expansion.

Anton Kharitonov, expert at Traders Union, sees the recent 3.85% surge in Charles River Laboratories as driven by short-term optimism after the earnings beat and upward guidance revision. He notes that bullish signals dominate the technical setup, but highlights that the price is now near resistance at $355.79 with high session volatility. Kharitonov remains cautious, pointing out the risk of a reversal if CRL loses support at $344.99. He believes buy-side sentiment is strong but sees overstated confidence in future gains. "Traders should be wary of chasing this rally without tight stops, as the upside gap may soon attract profit-taking and trigger a corrective pullback."

Viktoras Karapetjanc, expert at Traders Union, views the raised 2026 GAAP EPS guidance and solid organic growth as clear signs of accelerating demand and management confidence. He is encouraged by the company's strategic acquisitions to broaden its service portfolio. Karapetjanc sees a robust outlook, supported by strengthening fundamentals and investor appetite. "With the bullish structure intact and further growth expected, CRL offers multiple setups for upside breakout in the coming sessions."

Sholanke Dele, market strategist, is skeptical that recent gains can be sustained. He notes investor enthusiasm is high post-earnings, yet questions if growth will keep pace with rising expectations. Macro conditions could quickly shift sentiment if broader markets falter. "I see the upside as limited for now, and traders should prepare for renewed volatility if momentum fades."

Bullish momentum maintained as price nears resistance and signals stay neutral

Charles River Laboratories is trading above its 20-day, 50-day, and 200-day moving averages ($332.42, $305.63, and $224.57 respectively), confirming a bullish structure across short-, medium-, and long-term timeframes. The near-term ceiling is at $355.79 and the closest floor is at $344.99, with the Ichimoku Kijun at $332.61 serving as additional trend support. Momentum signals are strong, with both the MACD and Average Directional Index (ADX) indicating bullish conditions. The Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) readings are all neutral, meaning none are in overbought or oversold territory. Bull/Bear Power (BBP) is positive at 2.61, showing buyers are currently dominant. CRL is up $13.01 or 3.85% so far today after an upside gap of about $7.5 (2.22%). The current price sits near the session highs, and intraday volatility stands at 0.19%. The intraday tone is strong with buyers pressing toward resistance levels.

Previously it was reported that Charles River Laboratories' prior rally was driven primarily by technical momentum in the absence of significant company news or external catalysts. The current article adds fundamental strength to the technical setup with robust earnings and guidance revisions, and traders should watch for a potential breakout above $355.79 as confirmation of sustained upside momentum.

Source of Data: CRL Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.